---

July 22, 2026 – Researchers at the University of Oxford have launched the first Phase 1 clinical trial of a vaccine specifically developed against the Bundibugyo ebolavirus (BDBV). This marks an important milestone in efforts to strengthen preparedness against one of the less common but potentially deadly Ebola virus species. The investigational vaccine is designed to address a significant gap in current Ebola prevention, as no licensed vaccine is currently available for the Bundibugyo strain (Wise, 2026).

The vaccine candidate, ChAdOx1 BDBV, is being evaluated in a Phase 1 study involving 50 healthy adult volunteers aged 18 to 55 years. The trial will assess the vaccine's safety, tolerability, and ability to generate an immune response before advancing to larger clinical studies (University of Oxford, 2026).

The vaccine was developed in just eight weeks using Oxford's well-established ChAdOx1 viral vector platform, the same technology that underpinned the Oxford-AstraZeneca COVID-19 vaccine. The rapid transition from vaccine design to first-in-human testing demonstrates how platform technologies can accelerate responses to emerging infectious disease outbreaks (University of Oxford, 2026).

Unlike Ervebo, the licensed Ebola vaccine that targets the Zaire ebolavirus, the new vaccine focuses on the Bundibugyo species. The World Health Organization has indicated that currently available Ebola vaccines should not be relied upon to protect against Bundibugyo virus because sufficient evidence of cross-protection is lacking (Baraniuk, 2026).

The trial follows increased international concern over recent Bundibugyo Ebola outbreaks in East and Central Africa. In response, the Coalition for Epidemic Preparedness Innovations (CEPI) has committed substantial funding to accelerate the development of multiple Bundibugyo-specific vaccine candidates, including Oxford's programme (Baraniuk, 2026).

To support rapid deployment should clinical development prove successful, the Serum Institute of India has already manufactured approximately 620,000 investigational doses of the vaccine. Future studies are expected to expand into Uganda through collaborations with the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine Uganda Research Unit, pending regulatory approvals (University of Oxford, 2026).

The study represents more than a scientific milestone—it reflects the growing importance of rapid vaccine development platforms in responding to region-specific infectious disease threats. For Africa, where Ebola outbreaks continue to pose significant public health risks, the development of vaccines targeting multiple Ebola virus species could strengthen epidemic preparedness and improve future outbreak response.

Although the vaccine remains investigational and will require further clinical evaluation before regulatory approval, the launch of this Phase 1 trial is an important step toward expanding the global arsenal of Ebola vaccines beyond protection against the Zaire strain.

---

References 

Baraniuk, C. (2026). Ebola: Three vaccines rushed into development for Bundibugyo outbreak. The BMJ, 393, e557985.

University of Oxford. (2026, July 13). World's first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group. University of Oxford.

Wise, J. (2026). Ebola vaccine: Oxford starts UK trial against Bundibugyo strain. The BMJ, 394, e100286. https://doi.org/10.1136/bmj-2026-100286